MoveSurge Every market-moving story. Fast. Clear. Complete.

Sign In Start Pro — $29 for 7 days$29 Pro

Never miss the news that moves markets. Every market-moving story. Fast. Clear. Complete. Wide coverage Global markets and U.S. stocks of every size. Fast Important news reaches you as it breaks. Clear Plain words and extra context only when you need it.

Analyst-led coverage since 2006 Covers: Global markets, all sizes of U.S. stocks, central banks, economic data, politics, oil, gold, and more. Direct sources included

Insights › Stocks

Akebia Therapeutics (AKBA) News Today

Every AKBA headline we timestamp, with the price move measured one minute and fifteen minutes after it crossed the tape.

Our analysis

Why Is Akebia Therapeutics Stock Down Today?

Akebia beat Q2 2026 estimates as its newer drug Vafseo kept growing, even as total revenue fell year-over-year because its older drug Auryxia lost ground to …

Related coverage

The next market-moving story will not wait

See the important story while it still matters.

Seven market specialists bring experience dating back to 2006. MoveSurge adds the speed, coverage, and clear format built for today’s market.

Wide coverageGlobal markets and every size of U.S. stock Clear in secondsThe story, source, context, and measured move together Built on evidenceReal headlines, timestamps, prices, and trusted sources

Start Pro — $29 for 7 days View the live feed $29 today for 7 days. Then renews at the selected plan unless cancelled. Information only—no trade calls.